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We identiﬁ  ed Dobrava-Belgrade virus infection in Turkey 
(from a strain related to hantavirus strains from nearby 
countries) in a patient who had severe symptoms leading 
to panhypopituitarism, but no known risk for hantavirus. Our 
ﬁ  ndings emphasize the need for increased awareness of 
hantaviruses in the region and assessment of symptomatic 
persons without known risk factors for infection.
H
emorrhagic fever with renal syndrome (HFRS) is 
caused by infection with hantaviruses. Most patients 
with HFRS recover completely, but acute and chronic 
complications may develop. HFRS patients with severe 
lung involvement resembling hantavirus cardiopulmonary 
syndrome have been described (1). In addition, pituitary 
hemorrhage, followed by hypopituitarism, is a possible 
complication of HFRS. Involvement of the pituitary gland 
has been observed in some patients infected with Puumala 
virus, a hantavirus commonly found in western and central 
Europe (2–4).
We report on a patient who experienced shock, 
pulmonary failure, and panhypopituitarism as complications 
of HFRS. By testing for neutralizing antibodies and by 
ampliﬁ   cation and molecular characterization of virus 
samples, we identiﬁ  ed the causative pathogen as a strain of 
Dobrava-Belgrade virus (DOBV) that is closely related to 
a hantavirus strain typically carried by the yellow-necked 
ﬁ  eld mouse (Apodemus ﬂ  avicollis), strain DOBV-Af. 
The Case-Patient
A 34-year-old man with fever (38°C), tender cervical 
lymph nodes, and symptoms of pharyngeal infection was 
admitted to a hospital in Istanbul, Turkey on February 3, 
2010. His blood pressure was 120/70 mm Hg and heart 
rate was 96 beats/min. Laboratory ﬁ  ndings  included 
thrombocytopenia (63,000 platelets/mm3 [reference 130–
450×103 platelets/mm3]) and mild elevation of transaminase 
levels (alanine transaminase  95 IU/L [reference 10–40 
IU/L]; Aspartate aminotransferase 99 IU/L [reference 15–
40 IU/L]) (Table 1). Results of urinalysis, chest radiograph, 
and ultrasound of the abdomen were normal. Diarrhea 
developed during the ﬁ   rst day of hospitalization, and 
conjunctival suffusion was observed on ocular examination. 
Ciproﬂ  oxacin was given to treat suspected salmonellosis at 
a dosage of 400 mg every 12 hours.
On day 2 of hospitalization, the patient became 
oliguric and hypotensive. He had persisting fever. His 
platelet count decreased to 20,000/mm3, and his serum 
creatinine level increased to 1.8 mg/dL (reference 0.7–1.2 
mg/dL). Urinalysis results showed microscopic hematuria 
and proteinuria. Results of a transthoracic echocardiogram 
showed heart chambers of normal size, a left ventricular 
ejection fraction of 60%, and moderate pericardial 
effusion. The patient was transferred to the intensive care 
unit. Broad-spectrum antimicrobial drugs were initiated as 
treatment for suspected sepsis, and platelet and albumin 
transfusions were given as supportive therapy.
On day 3 of hospitalization, the patient experienced 
tachycardia, petechial lesions appeared on his extremities, 
and his platelet count dropped to 13,000/mm3. Results 
of a bone marrow aspiration showed proliferation of 
histiocytes and prominent hemophagocytosis. Intravenous 
methylprednisolone therapy (100 mg/day) was started. 
Septic shock developed in the patient, and inotropic therapy 
was initiated. On the same day, acute respiratory distress 
syndrome developed, and assisted ventilation was started. 
Results of a thoracic computerized tomographic scan 
showed focal inﬁ  ltration on the upper zone of the left lung 
and minimal pleural effusion on the right lung. Results of 
abdominal computerized tomographic scan revealed ascites 
and multiple mesenteric lymphadenomegalies. On the 
basis of these clinical and laboratory ﬁ  ndings, hantavirus 
infection was suspected. Blood samples were obtained for 
hantavirus testing, and oral ribavirin was added at an initial 
dose of 30 mg/kg, followed by 15 mg/kg every 6 hours 
for 4 days, then 7.5 mg/kg for 6 days. On the same day, 
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hemoﬁ  ltration was started and continued for 6 consecutive 
days. The patient’s urinary output gradually increased, 
pulmonary symptoms regressed, and his ventilation tube 
was removed on day 12 of hospitalization. The patient 
stayed in the intensive care unit for 18 days and was then 
transferred to a standard care unit.
No microbial growth was observed in the cultures 
of samples taken during the ﬁ  rst days of hospitalization. 
Serum samples were tested for antibodies against a panel of 
pathogens, including Salmonella typhi, S. paratyphi A and 
B, Brucella spp., HIV, Crimean-Congo hemorrhagic fever 
virus, Epstein-Barr virus, cytomegalovirus, parvovirus 
B19, adenovirus, dengue virus, Rickettsia spp., Leptospira 
spp., Treponema pallidum, and hepatitis viruses A, B, C, 
and E. Results of these serologic tests were negative or 
inconspicuous. Results of PCR analysis conducted for 
leptospirosis, respiratory viruses, and cytomegalovirus 
were below the detection limit of the assays.
Serologic testing for hantavirus was performed by 
using the recomLine Bunyavirus IgG/IgM immunoassay 
(Mikrogen, Neuried, Munich, Germany); results showed 
strong reactivity for IgG and IgM antibodies, indicating 
an acute hantavirus infection. The blot data provided 
evidence of an infection with DOBV; to conﬁ  rm  the 
results, we performed serotyping by using focus reduction 
neutralization tests (Table 2). The results conﬁ  rmed  a 
DOBV infection most likely caused by a strain of DOBV-
Af. Reverse transcription PCR results for hantaviral RNA 
were positive for the ﬁ   rst acute-phase blood sample. 
Subsequent nucleotide sequence determination of parts 
of the 3 genomic segments and molecular phylogenetic 
analysis of these small, medium (Figure 1), and large gene 
sequences (data not shown) showed that the isolate was 
most closely related to DOBV-Af.
On day 19 of hospitalization, the patient displayed 
generalized weakness. The results of the basal levels 
of hormonal studies are shown in Table 1. On day 20 
of hospitalization, panhypopituitarism was diagnosed. 
Hormone replacement therapy using hydrocortisone, 
thyroxin, and testosterone was immediately initiated. On 
day 22 of hospitalization, magnetic resonance imaging 
showed pituitary hemorrhage and pituitary atrophy (Figure 
2). After the administration of hormone replacement 
therapy, symptoms improved markedly. The patient 
was discharged on day 33 of hospitalization. At the ﬁ  nal 
outpatient followup visit, the patient had normal urine 
output and his serum creatinine level was 1.5 mg/dL. 
His pulmonary examination results and chest radiograph 
ﬁ  ndings were normal, but he continued to require hormonal 
replacement therapy at the 16th month of followup care. 
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Table 1. Hematologic and biochemical parameters of DOBV hantavirus patient, Istanbul, Turkey, 2010* 
Laboratory test (reference range) 
Day of hospitalization 
0  12345 1 5   20 71
Leukocytes, u 10
3 cells/mm
3 (4.5–11)  5.8 9.9 15.2  27.6 24  25 11.3 4.7 7.7 
Hemoglobin, g/dL (11.7–15.5)  16 16.5 18  16 13.3  10.7 8.2 8.9 12.1 
Hematocrit, % (36–46)  46.7 48 51.8  45.2  38.3  31.2  24.6 27 36.6 
Platelets, u 10
3/mm
3 (130–450)  63 19 20 13 37 55  180  171  254 
ALT, U/L (10–40)  95 92 58 67  157  539  79 60 20 
AST, U/L (15–40)  99  117  –†  –  497 2234 106  84  25 
BUN, mg/dL (4.67–23.3)  –  18 23 30 41 41  129  74 19 
Creatinine, mg/dL (0.7–1.2)  –  0.8 1.8 2.4 3.3 3.1 7.3 6.4  1.92 
aPTT, s (4–40)  –  39 43  – 32.5  37.1  30.8 –  – 
PT, s (10–14 s)  – 13.3  11.6 – 17.5  20  14.1 –  – 
Ferritin, ng/mL (15–200)  –  5,304  – –  14,036  – – – – 
TSH, U/mL (0.4–4.2)  – 1.71 –  –  –  –  – 2.83  0.92 
Free thyroxin, pmol/L (10.3–23.2)  – – – – – – –  0.18  14.3 
Cortisol, ȝg/dL (6.2–19.4)  –  –  –  –  – 45.0 – 0.98  4.7 
ACTH, pg/mL (0–46)  –  –  –  –  – 3.02 – 6.80 – 
ADH, pg/mL (0.8–4.5)  – – – – – – –  2.2  – 
Total testosterone, ng/mL (2.8–8.0)  – – – – – – –  <0.025  1.9 
LH, mIU/mL (1.7–8.6)  – – – – – – –  <0.1  – 
FSH, mIU/mL (1.5–12.4)  – – – – – – –  0.66  – 
Prolactin, mIU/mL (4.6–21.4)  – – – – – – –  10.05  – 
Somatomedin-C/IGF-1, ng/mL (115–307)  – – – – – – –  <25  – 
*DOBV, Dobrava-Belgrade virus; ALT, alanine transaminase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; aPTT, activated partial 
thromboplastin time; PT, prothrombin time; TSH, thyroid stimulating hormone; ACTH, adrenocorticotropic hormone; ADH, antidiuretic hormone; LH, 
luteinizing hormone; FSH, follicle-stimulating hormone; IGF, insulin-like growth factor. 
†Test not performed. 
Table 2. Characterization of DOBV hantavirus in a patient’s serum by focus reduction neutralization tests, Istanbul, Turkey, 2010* 
Day of hospitalization  Focus reduction neutralization test endpoint titer 
Puumala hantavirus  Hantaan virus  DOBV-Aa (strain SK)  DOBV-Af (strain Slo) 
5 <1:40  <1:40  1:640  1:1,280 
26 <1:40  <1:40  1:160  1:320 
*DOBV, Dobrava-Belgrade virus; Aa, Apodemus agrarius; Af, Apodemus flavicollis; SK, strain Slovakia; Slo, strain Slovenia.  Conclusions
The general symptoms and results of the serologic 
tests and molecular analyses for this patient were consistent 
with a hantavirus infection. After the acute phase of the 
illness, characterized by renal and pulmonary failure, 
panhypopituitarism developed in the patient. Pituitary 
hemorrhage and atrophy were observed on the magnetic 
resonance image. Case reports have documented that 
pituitary hemorrhage followed by panhypopituitarism may 
complicate HFRS (2–4), and Puumala virus was reported 
as the causative agent in most of these cases. In addition, 
hormonal deﬁ   ciencies have been shown to be common 
features of Puumala virus infections, and chronic hormonal 
deﬁ   cits develop in some patients (5). Our ﬁ  ndings 
demonstrate that development of hypopituitarism can also 
be associated with infection by DOBV. Since the patient 
does not belong to any groups that have high exposure to 
hantaviruses (such as farmers, forest workers, and military 
recruits) and did not report any travel in hantavirus-endemic 
areas, the source of infection remains unclear.
In contrast to what is known about hantavirus presence 
in other Balkan states, little is known about the distribution, 
diversity, or host range of hantaviruses in Turkey (6). In 
2009, a hantavirus outbreak occurred in Turkey; 3 of the 
5 infected persons died (7). Serologic assays have been 
used to detect DOBV infection in patients in Turkey, but 
focus reduction neutralization tests have not been used for 
serotyping. DOBV RNA was found only in 1 urine sample 
from a hantavirus-infected patient from Turkey; however, 
sequence data were not provided (8). Prevalence studies 
of rodents collected in Turkey revealed 6% seropositivity 
to Puumala virus in Microtus voles and no appearance of 
hantavirus antibodies in the Apodemus species of rodents (9). 
Focus reduction neutralization testing and virus sequencing 
conﬁ  rmed that the patient in our study was infected with 
DOBV-Af. This strain is associated with A. ﬂ  avicollis ﬁ  eld 
mice and yet has not been reported in animals in Turkey 
(see 10,11 for the molecular classiﬁ  cation of Apodemus 
spp.–associated DOBV virus lineages).
This case should alert physicians that hantavirus 
infection should be considered in the differential diagnosis 
of patients who have high fever and thrombocytopenia, 
including those without known risk factors for hantavirus 
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Figure 2. Magnetic resonance images 
showing hemorrhage of the pituitary 
gland and pituitary atrophy as indicated 
by arrows. A) T1-weighted coronal image 
shows high signal intensity on the right 
side of the adenohypophysis consistent 
with hemorrhage. B) T2-weighted sagittal 
image shows decreased pituitary gland 
height and heterogenous low signal 
intensity of the central adenohypophysis 
due to hemorrhagic infarction.
Figure 1. Molecular phylogenetic analysis of small (S) and medium 
(M) gene segments. Consensus neighbor-joining phylogenetic 
tree (Tamura-Nei 93 evolutionary model) of hantavirus strains was 
constructed as described (9) based on partial sequences of the 
S (panel A) and M segment (panel B). Bootstrap values >70%, 
calculated from 10,000 replicates, are shown at the tree branches. 
Sequences taken from GenBank are indicated by their accession 
numbers. SAAV Est, Saaremaa virus from Estonia; DOBV AnoP, 
Dobrava-Belgrade virus (lineage DOBV-Af) from Greece; DOBV 
Slo, Dobrava-Belgrade virus (lineage DOBV-Af) from Slovenia; 
DOB SK, Dobrava-Belgrade virus (lineage DOBV-Aa) from 
Slovakia; HTNV, Hantaan virus; SEOV, Seoul virus; ANDV, Andes 
virus; SNV, Sin nombre virus; PUUV, Puumala virus; TULV, Tula 
virus; PHV, Prospect Hill virus. Scale bars indicate an evolutionary 
distance of 0.1 substitutions per position.Dobrava Hantavirus and Panhypopituitarism
exposure. Since severe hormonal deﬁ   ciencies are life-
threatening, neuroendocrinologic complications should 
be taken into account and the endocrine status should be 
investigated to prevent panhypopituitarism even after 
recovery from HFRS.
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